Free Trial
NASDAQ:CLSD

Clearside Biomedical (CLSD) Stock Price, News & Analysis

Clearside Biomedical logo
$0.82 +0.02 (+1.99%)
Closing price 07/3/2025 03:14 PM Eastern
Extended Trading
$0.82 0.00 (-0.24%)
As of 07/3/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Clearside Biomedical Stock (NASDAQ:CLSD)

Key Stats

Today's Range
$0.81
$0.83
50-Day Range
$0.74
$0.90
52-Week Range
$0.70
$1.65
Volume
27,100 shs
Average Volume
360,655 shs
Market Capitalization
$63.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75
Consensus Rating
Buy

Company Overview

Clearside Biomedical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

CLSD MarketRank™: 

Clearside Biomedical scored higher than 29% of companies evaluated by MarketBeat, and ranked 2461st out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Clearside Biomedical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Clearside Biomedical has only been the subject of 3 research reports in the past 90 days.

  • Read more about Clearside Biomedical's stock forecast and price target.
  • Earnings Growth

    Earnings for Clearside Biomedical are expected to decrease in the coming year, from ($0.48) to ($0.50) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Clearside Biomedical is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Clearside Biomedical is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Clearside Biomedical's valuation and earnings.
  • Percentage of Shares Shorted

    0.48% of the float of Clearside Biomedical has been sold short.
  • Short Interest Ratio / Days to Cover

    Clearside Biomedical has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Clearside Biomedical has recently increased by 181.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Clearside Biomedical does not currently pay a dividend.

  • Dividend Growth

    Clearside Biomedical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.48% of the float of Clearside Biomedical has been sold short.
  • Short Interest Ratio / Days to Cover

    Clearside Biomedical has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Clearside Biomedical has recently increased by 181.00%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Clearside Biomedical this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for CLSD on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Clearside Biomedical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Clearside Biomedical insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.20% of the stock of Clearside Biomedical is held by insiders.

  • Percentage Held by Institutions

    Only 18.75% of the stock of Clearside Biomedical is held by institutions.

  • Read more about Clearside Biomedical's insider trading history.
Receive CLSD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

CLSD Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Headlines

CLSD Stock Analysis - Frequently Asked Questions

Clearside Biomedical's stock was trading at $0.95 at the beginning of the year. Since then, CLSD stock has decreased by 13.5% and is now trading at $0.8220.

Clearside Biomedical, Inc. (NASDAQ:CLSD) announced its earnings results on Wednesday, May, 14th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.01. The business had revenue of $2.33 million for the quarter, compared to analyst estimates of $0.20 million.

Clearside Biomedical (CLSD) raised $50 million in an IPO on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), NVIDIA (NVDA), T2 Biosystems (TTOO), Advanced Micro Devices (AMD) and (ZLTQ) (ZLTQ).

Company Calendar

Last Earnings
5/14/2025
Today
7/04/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CLSD
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.75
High Stock Price Target
$6.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+477.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$34.35 million
Net Margins
-818.57%
Pretax Margin
-799.60%

Debt

Sales & Book Value

Annual Sales
$1.66 million
Price / Cash Flow
N/A
Book Value
($0.51) per share
Price / Book
-1.61

Miscellaneous

Free Float
72,891,000
Market Cap
$63.88 million
Optionable
Optionable
Beta
2.05

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:CLSD) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners